Patients With Persistent Objectified Gastroesophageal Reflux and Reflux-Associated Symptoms Despite PPI-Therapy With 40mg Esomeprazole Clinical Trial
It has been reported that Baclofen is an appropriate tool in the therapeutic management of
Gastroesophageal Reflux Disease. To objectify gastroesophageal reflux combined
pH-metry/impedance monitoring was applied to patients with persistent reflux-associated
symptoms despite PPI-therapy (40mg esomeprazole for 2 weeks). After provement of
pathological findings in the test PPI-dosage was escalated to double standard-dosage for
another for weeks. In case of persistent symptoms another ph-metry/impedance monitoring was
performed. In case of pathological findings additional baclofen was administered to the
therapeutic regime. After 3 months another ph-metry/impedance monitoring was performed. At
the time point of the tests a questionnaire was completed.
Aim of the study was to evaluate the influence of high dosage PPI-therapy and additional
baclofen in patients with persistent symptoms and objectified gastroesophageal reflux.
n/a
Time Perspective: Prospective